Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).
Details
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_EA3FA50DC390
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).
Journal
Open forum infectious diseases
Working group(s)
Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
Contributor(s)
Abela I., Aebi-Popp K., Anagnostopoulos A., Battegay M., Bernasconi E., Braun D.L., Bucher H., Calmy A., Cavassini M., Ciuffi A., Dollenmaier G., Egger M., Elzi L., Fehr J., Fellay J., Furrer H., Fux C., Günthard H., Hachfeld A., Haerry D., Hasse B., Hirsch H., Hoffmann M., Hösli I., Huber M., Jackson-Perry D., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kouyos R.D., Kovari H., Kusejko K., Labhardt N., Leuzinger K., de Tejada B.M., Marzolini C., Metzner K.J., Müller N., Nemeth J., Nicca D., Notter J., Paioni P., Pantaleo G., Perreau M., Rauch A., Salazar-Vizcaya L., Schmid P., Speck R., Stöckle M., Tarr P., Trkola A., Wandeler G., Weisser M., Yerly S., Amico P., Aubert J.D., Banz V., Beckmann S., Beldi G., Berger C., Berishvili E., Berzigotti A., Binet I., Bochud P.Y., Branca S., Bucher H., Catana E., Cairoli A., Chalandon Y., De Geest S., De Rougemont O., De Seigneux S., Dickenmann M., Dreifuss J.L., Duchosal M., Fehr T., Ferrari-Lacraz S., Garzoni C., Golshayan D., Goossens N., Haidar F., Halter J., Heim D., Hess C., Hillinger S., Hirsch H.H., Hirt P., Hoessly L., Hofbauer G., Huynh-Do U., Immer F., Koller M., Laesser B., Lamoth F., Lehmann R., Leichtle A., Manuel O., Marti H.P., Martinelli M., McLin V., Mellac K., Merçay A., Mettler K., Mueller N.J., Müller-Arndt U., Müllhaupt B., Nägeli M., Oldani G., Pascual M., Passweg J., Pazeller R., Posfay-Barbe K., Rick J., Rosselet A., Rossi S., Rothlin S., Ruschitzka F., Schachtner T., Schaub S., Scherrer A., Schnyder A., Schuurmans M., Schwab S., Sengstag T., Simonetta F., Stampf S., Steiger J., Stirnimann G., Stürzinger U., Van Delden C., Venetz J.P., Villard J., Vionnet J., Wick M., Wilhelm M., Yerly P.
ISSN
2328-8957 (Print)
ISSN-L
2328-8957
Publication state
Published
Issued date
04/2023
Peer-reviewed
Oui
Volume
10
Number
4
Pages
ofad150
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).
Keywords
HIV, Organ transplant, SARS-CoV-2, Vaccine, randomized trial
Pubmed
Web of science
Open Access
Yes
Create date
26/01/2024 11:17
Last modification date
01/03/2024 8:06
Usage data
